Evidence map›Paper›PMID 41835341›Full record

ArticleTherapeutic advances in medical oncology2026

A phase II randomized placebo-controlled study of fisetin to improve physical function in breast cancer survivors: the TROFFi study rationale and trial design.

Jingran Ji, Catherine M Crespi, Lisa Yee, Yuliya A Zekster, Ali Al-Saleem, Laura Petersen, Catherine Lee, Nala Son, Claire Smith, Tamara Evans and 5 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05595499 (A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05595499 phase2recruitingnot on this map

A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2023 to 2028Enrolled88ConditionsAnatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8ArmsBiospecimen Collection, Fisetin, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Jingran JiDepartment of Medicine, Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0002-7284-0709
Catherine M CrespiDepartment of Medicine, Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Lisa YeeDepartment of Surgery, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Yuliya A ZeksterDepartment of Medicine, Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-0800-4631
Ali Al-SaleemDepartment of Medicine, Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Laura PetersenDepartment of Medicine, Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Catherine LeeDepartment of Medicine, Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Nala SonDepartment of Medicine, Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Claire SmithDepartment of Medicine, Hematology Oncology, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.
Tamara EvansCenter for Advanced Geroscience, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.
Tamar TchkoniaCenter for Advanced Geroscience, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.
James L KirklandCenter for Advanced Geroscience, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0003-1676-4905
George A KuchelDepartment of Medicine, University of Connecticut, Mansfield, CT, USA.
Harvey Jay CohenDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Mina S SedrakDavid Geffen School of Medicine at UCLA, 650 Charles Young Drive South, Room A2-125 CHS, Los Angeles, CA 90095-6900, USA.ORCID https://orcid.org/0000-0002-8379-391X

Funding

Translational Geroscience NetworkR33AG061456 · NIA · MAYO CLINIC ROCHESTER · PI JAMES L. KIRKLAND, STEPHEN B. KRITCHEVSKY · 2019 to 2026
$6.2M
Using Senolytics to Improve Physical Function in Older Breast Cancer SurvivorsR21CA277660 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SEDRAK, MINA S · 2023 to 2024
$422k
NCI NIH HHS R21 CA277660NIA NIH HHS R33 AG061456
6 · The paper itself

Abstract

Background: Postmenopausal breast cancer survivors treated with neo/adjuvant chemotherapy often experience persistent declines in physical function that fail to resolve after treatment. One mechanism thought to underlie this lasting impairment is cellular senescence, a fundamental process of aging that contributes to frailty and functional decline. Chemotherapy induces senescence, and preclinical studies show that targeting senescent cells with senolytics can reduce inflammation and improve physical function. These findings have generated a strong interest in translating senolytic therapies to humans; however, no study to date has evaluated the effects of senolytics on physical function in postmenopausal breast cancer survivors. Objective: To evaluate the effects of targeting senescence with the oral senolytic agent fisetin on physical function in chemotherapy-treated postmenopausal breast cancer survivors. Design: A multicenter, phase II, randomized, double-blind, placebo-controlled trial. Methods and analysis: Eighty-eight postmenopausal women with early-stage, high-risk breast cancer who completed neo/adjuvant chemotherapy within the past 12 months and have diminished physical function, defined by a 6-minute walk distance (6MWD) <400 m, will be randomized 1:1 to receive either placebo or fisetin (20 mg/kg/day) on days 1-3 of a 14-day cycle for four cycles. The primary endpoint is the change in the 6MWD from baseline to end of treatment. Ethics: The study has been approved by the institutional review boards at participating sites. Discussion: This is one of the first studies to test whether targeting senescence with an oral senolytic agent, fisetin, can mitigate physical function decline in postmenopausal breast cancer survivors treated with neo/adjuvant chemotherapy. Promising results would provide the preliminary evidence needed to support a larger, confirmatory trial evaluating fisetin's efficacy in this population. If successful, this approach could fill an important unmet clinical need, as no pharmacological therapies currently exist to prevent or treat chemotherapy-related declines in physical function among postmenopausal breast cancer survivors. Trial registration: ClinicalTrials.gov NCT05595499.

Indexed as

breast cancerchemotherapyclinical trialsgeriatric oncologynovel therapiesphase II trialsquality of lifesurvivorship

Identifiers

PMID41835341
PMCPMC12979913

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.